BUSINESS
Sumitomo Dainippon Files Rethio for Conditioning Treatment Prior to HSCT for Malignant Lymphoma
Sumitomo Dainippon Pharma said on April 2 that it has filed an application in Japan for Rethio (thiotepa) to extend its indication to “conditioning treatment prior to autologous hematopoietic stem cell transplantation (HSCT) for malignant lymphoma.” Rethio 100 mg for…
To read the full story
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





